Does Semax interact with alcohol?
No published studies have directly investigated the combination of Semax and alcohol, either in animals or humans. However, a lack of studied interactions does not equate to confirmed safety. Anyone combining Semax with alcohol does so without the support of any controlled research.
Alcohol acts as a central nervous system depressant. It enhances the activity of GABA receptors—increasing the brain's calming, inhibitory signals—while also inhibiting the activity of NMDA glutamate receptors, reducing the brain's excitatory signals. Put simply, alcohol simultaneously strengthens the brain's brakes and weakens its accelerator.
Semax works in essentially the opposite direction. It enhances glutamatergic synaptic transmission [1], amplifies dopaminergic system responses [2], increases BDNF [3], and activates brain networks associated with alertness and cognitive performance [4]. Combining substances with opposing effects on the central nervous system raises legitimate questions about whether they might partially neutralise each other, enter into unpredictable interactions, or under certain circumstances, induce effects stronger than each of these substances individually.
What could happen after combining Semax with alcohol?
Based on opposing pharmacological profiles, the most probable outcome of combining Semax with alcohol is the partial cancellation of each other's effects on brain activity. Alcohol's GABA-enhancing and glutamate-suppressing effects would likely blunt Semax's cognitive activation, while its dopamine and serotonin-modulating effects might unpredictably alter the subjective experience of alcohol intoxication. This is theoretical reasoning based on known pharmacological properties, rather than documented research results of the combination.
One of the pharmacologically significant issues is the documented inhibition of enkephalin-degrading enzymes in human blood by Semax [5]. Enkephalins are the brain's own naturally occurring opioid-like calming peptides. When Semax inhibits the enzymes that break down these peptides, it prolongs their activity – effectively boosting the brain's natural opioid inhibitory signals. Alcohol also enhances opioid system activity through its own indirect mechanisms. Combining two substances, both increasing the activity of the brain's natural opioid system – even through entirely different pathways – could theoretically cause an additive central nervous system depression beyond the effect of each substance alone. This is a theoretical concern, not a documented interaction – however, it justifies caution.
Alcohol is also a well-established suppressor of BDNF expression in the brain – particularly in the hippocampus – and it is this suppression of BDNF that is directly linked to the detrimental effects of alcohol on memory and learning. The most consistent and powerful effect of Semax is an increase in BDNF in the very same brain areas that alcohol most harms [3], [6]. Whether the BDNF-stimulating effects of Semax can significantly counteract the suppression of BDNF by alcohol has never been tested. It would be inappropriate to suggest that Semax protects the brain from the harmful effects of alcohol without direct evidence.
Does alcohol reduce the effectiveness of Semax?
Alcohol is likely to reduce the pro-cognitive effects of Semax during intoxication, given the opposing nature of their actions on the central nervous system. The neuronal activation, improved concentration and enhanced synaptic plasticity that Semax induces, through glutamatergic potentiation and dopaminergic modulation, would logically be counteracted by the concomitant suppression of these same systems by alcohol.
From a practical standpoint, combining an activating nootropic with a sedating intoxicant is inherently counterproductive to the goals for which most people use Semax — cognitive performance, learning, and focus. Semax’s efficacy for these purposes would most likely be diminished when used concurrently with alcohol, though the precise extent of this effect has not been quantified in any study.
Semax or other recreational substances
No published studies have investigated Semax in combination with cannabis, cocaine, or other recreational substances. Cannabis acts primarily through cannabinoid receptors and has complex effects on the dopaminergic, GABAergic, and glutamatergic systems – all of which overlap with the pharmacological targets of Semax. This makes their combination theoretically unpredictable without specific combination study data.
The dopaminergic-enhancing effect of Semax — its ability to amplify dopaminergic responses [2] — is particularly noteworthy for any substance that affects dopaminergic signalling. Amplifying an already enhanced dopaminergic response could theoretically provoke unexpected cardiovascular or psychiatric effects. In the complete absence of evidence, combining Semax with any recreational substance should be considered an ill-advised and potentially unpredictable practice.
Does Semax interact with SSRIs or antidepressants?
No published studies have directly investigated the interaction of Semax with SSRIs — selective serotonin reuptake inhibitors, a commonly prescribed class of antidepressants — or other antidepressants. However, several pharmacological considerations make this combination warrant careful thought.
SSRI work by blocking the reuptake of serotonin into nerve cells. By blocking this process, they increase the amount of serotonin available in the synapse – the space between nerve cells – effectively strengthening serotonin signalling.
Semax also increases serotonin turnover in the striatum [2] and exhibits documented antidepressant effects through mechanisms involving serotonergic activation and increased BDNF [7]. The combination of two factors, both enhancing serotonergic activity, raises a theoretical concern about serotonin syndrome – a potentially serious condition caused by excessive serotonin activity in the brain and body. Symptoms can range from agitation, rapid heart rate, and muscle tremors to more severe neurological effects in severe cases.
To be precise regarding the actual evidence: serotonin syndrome has not been reported in any Semax studies, and its effect on serotonin appears to be modulatory—gently tuning the system—rather than directly blocking reuptake like SSRIs. The extent of serotonin potentiation by Semax is likely modest compared to a dedicated SSRI, which lessens the practical risk. However, with a complete lack of safety data for the combination, individuals currently taking SSRIs, SNRIs, MAOIs, tricyclic antidepressants, or any other medication significantly affecting serotonin levels should discuss Semax use with their prescribing physician before combining these compounds.
A study with neonatal fluvoxamine – analysing Semax's ability to correct behavioural and neurochemical deficits induced by early-life SSRI exposure – provides indirect evidence that Semax and SSRIs affect overlapping neurochemical systems [8], reinforcing the importance of caution when combining them.
Does Semax interact with Adderall or Vyvanse?
No published studies have investigated Semax in combination with amphetamine-based medications, including Adderall or Vyvanse. This is a combination that warrants significant caution based on the available pharmacological evidence.
The most directly relevant finding is that Semax dramatically potentiates—that is, significantly amplifies—the dopamine-releasing effect of D-amphetamine in animal studies, eliciting far higher peak dopamine concentrations and a more pronounced motor stimulation than amphetamine alone [9], [2]. This effect was documented by microdialysis—a technique that directly measures brain fluid chemistry in real-time—and represents a biologically relevant interaction, rather than merely a theoretical concern.
If Semax amplifies the effects of dopamine release by D-amphetamine in animal models, there is a reasonable basis to expect that it may also amplify the cardiovascular and stimulant effects of therapeutic amphetamine drugs in humans. This could potentially increase heart rate, blood pressure, anxiety, and the risk of excessive stimulation beyond therapeutic intent.
This doesn't mean the combination is definitively dangerous — however, it does mean that individuals taking prescription stimulants like Adderall or Vyvanse should not add Semax without a clear conversation with their prescribing doctor. The dopaminergic-enhancing mechanism is the strongest and most directly documented concern regarding pharmacological interactions throughout Semax's interaction profile.
Does Semax interact with stimulants in general?
The same concern regarding dopaminergic enhancement that applies to amphetamine-based drugs essentially extends to other stimulants that operate via dopamine-related mechanisms, including methylphenidate (sold under the trade names Ritalin and Concerta) and modafinil, a wakefulness-promoting drug.
Semax amplifies the dopaminergic system's response to stimulation [9] — a property suggesting that it sensitises dopaminergic circuits to react more intensely to any dopaminergic stimulus, not just amphetamine. Whether this enhancement extends to other stimulant mechanisms has not been directly tested, however, the precautionary principle applies.
Combining Semax with any stimulant medication or supplement without medical supervision constitutes a pharmacologically significant combination with a credible mechanism for potentially enhanced and unwanted stimulation of the cardiovascular and central nervous systems.
Does Semax interact with blood pressure medication?
Semax has documented effects on the cardiovascular system. These include modulation of sympathetic nervous system activity [10], reduction in sympathetic nerve density in blood vessel walls after myocardial infarction [11], anti-thrombotic effects [12], and changes in how blood vessels respond to stress signals [11]. These cardiovascular effects provide a credible basis for interactions with blood pressure medications, although no study has directly investigated this combination.
The concern isn't that Semax dramatically raises or lowers blood pressure on its own – it doesn't appear to do so at the doses studied. Rather, its sympathetic nervous system modulating effects could alter how hypotensive medications – prescribed to lower blood pressure – work in the body. This could potentially cause an additive blood pressure drop or modify the expected response to the medication.
Individuals taking beta-blockers, ACE inhibitors, calcium channel blockers, or other blood pressure medications should be aware that the cardiovascular effects of Semax have not been studied in the context of concurrent hypotensive therapy. Consultation with a cardiologist or physician is strongly advised before adding Semax to a treatment regimen.
Semax should not be combined with the following medications: * **Monoamine Oxidase Inhibitors (MAOIs)**: This includes medications like isocarboxazid, phenelzine, selegiline, and tranylcypromine. Combining Semax with MAOIs can lead to a dangerous increase in blood pressure. * **Other Stimulant Medications**: If you are taking other prescription or over-the-counter medications that stimulate the central nervous system, consult your doctor before taking Semax. This can include some ADHD medications or decongestants. * **Certain Antidepressants**: While some interactions are less common, it's prudent to discuss any antidepressant use with your doctor, especially those that affect serotonin or dopamine levels. * **Medications affecting blood pressure**: Due to Semax's potential effect on blood pressure, it's advisable to consult your doctor if you are taking medications to manage hypertension or hypotension. **It is crucial to inform your doctor or pharmacist about all medications, supplements, and herbal products you are currently taking before starting Semax. They can provide personalized advice and assess potential interactions.**
Based on pharmacological reasoning from available evidence, the combinations requiring the greatest caution are as follows.
Amphetamine-based stimulants, such as Adderall and Vyvanse, are of greatest concern due to their documented dopaminergic-enhancing effect shown in animal studies [9]. Serotonin-active agents, including SSRIs, SNRIs, and MAOIs, warrant caution due to overlapping serotonergic effects and the theoretical risk of excessive serotonin system activation [2]. Anticoagulant and antiplatelet drugs—including warfarin, heparin, aspirin, and clopidogrel—raise concern due to Semax's own documented fibrinolytic and anticoagulant effects, which could amplify bleeding risk when combined with other blood thinners [12]. Antiepileptic drugs used for seizure disorders also require caution, considering EEG changes observed in some patients taking Semax [13] and the general principle that neuronal excitability-modifying compounds may have unpredictable interactions with anticonvulsants.
The list is based on pharmacological reasoning, not documented case reports, as no formal drug interaction studies for Semax have been published.
Does Semax interact with other nootropics?
No published studies have formally investigated Semax in combination with other nootropic compounds. However, pharmacological reasoning from the individual compound profiles provides a framework for thinking about which combinations are likely to be relatively safe and which require more caution.
The general rule is that compounds sharing pharmacological targets may induce additive or synergistic effects – meaning their combined effect is equal to or greater than the sum of their individual effects. This can be beneficial when both compounds are neuroprotective, but could be problematic if the shared effect carries a dose-dependent risk.
Racetam nootropics — including piracetam, aniracetam, phenylpiracetam, and oxiracetam — primarily function by modulating AMPA glutamate receptors and the acetylcholine system. Semax also demonstrates documented activity at metabotropic glutamate receptors [14] and modulates acetylcholine receptor binding [15], indicating these compounds share some pharmacological territory. In comparative nootropic studies, Semax and piracetam were tested side-by-side in amnesia models [16] without reports of dramatic adverse interactions. Combining racetams with Semax is likely among lower-risk nootropic combinations based on pharmacological overlap, although direct safety data for the combination remains absent.
Phenylpiracetam is a more stimulating variant of the racetam class with added stimulant-like properties. Combining it with the dopaminergic-enhancing effects of Semax creates more theoretical overlap with the concerns regarding stimulant interactions discussed above. The more stimulating the nootropic compound considered, the more significant the concern about dopaminergic amplification becomes.
Does Semax interact with NAD+ or NAD precursors?
No published research has examined the combination of Semax with NAD+ precursors such as nicotinamide riboside (NR) or nicotinamide mononucleotide (NMN). NAD+ – nicotinamide adenine dinucleotide – is a molecule that plays a crucial role in cellular energy production. NAD+ precursors are supplements taken to boost NAD+ levels in the body, supporting mitochondrial function, DNA repair, and healthy ageing.
NAD+ precursors primarily act via metabolic and mitochondrial pathways, rather than direct neurotransmitter receptor systems. Pharmacological overlap between NAD+ metabolism and Semax's main mechanisms - neurotrophic factor upregulation, GABA and glutamate modulation, and dopaminergic system sensitisation - is relatively limited, suggesting a lower inherent risk of significant interaction.
However, both Semax and NAD+ precursors affect mitochondrial function. Semax does this via BDNF-driven neuroprotection involving mitochondrial membrane stabilisation [17], whereas NAD+ directly supports the electron transport chain – a biochemical process inside mitochondria that produces cellular energy. Whether these effects are simply additive or engage in more complex interactions remains unstudied. The combination therefore cannot be characterised as safe or unsafe based on available evidence.
Does Semax interact with thyroid medication?
No published studies have investigated the interaction of Semax with thyroid medications such as levothyroxine or liothyronine—synthetic thyroid hormones commonly prescribed for hypothyroidism. Thyroid hormones exert broad effects on brain function, neurotransmitter receptor sensitivity, and overall metabolic rate—all of which could theoretically impact how Semax behaves in the body.
Thyroid hormones affect BDNF expression, serotonin receptor sensitivity, and dopaminergic function in a manner that overlaps with Semax's pharmacological targets, making this combination theoretically complex, even if no direct interaction data exists. Individuals taking thyroid medication and considering Semax should discuss this with their endocrinologist – especially if they have been recently diagnosed or are still seeking a stable medication dosage.
Does Semax interact with supplements?
Most common dietary supplements - including standard vitamins, minerals, fish oil, and basic herbal supplements - are unlikely to interact significantly with Semax, given the absence of shared receptor targets with its known mechanisms.
A few specific supplements warrant more careful consideration. St John's Wort – a herbal supplement that acts as a natural serotonin reuptake inhibitor, using a similar mechanism to pharmaceutical SSRIs – should be combined with Semax with the same caution as pharmaceutical SSRIs, due to the theoretical risk of additive serotonergic effects.
Supplements with significant dopaminergic activity — such as mucuna pruriens, a plant extract containing L-DOPA (a direct dopamine precursor), or high doses of tyrosine — interact with the same dopaminergic pathways that Semax sensitises. The concern about dopaminergic potentiation discussed in the stimulants section also applies here, though likely with less force due to the more modest dopaminergic effects of these supplements compared to prescription drugs.
Supplements with antiplatelet and fibrinolytic properties — including high-dose fish oil, vitamin E, Ginkgo biloba, and garlic extracts — could theoretically add to Semax's own fibrinolytic and antiplatelet effects [12], creating a small but real additive risk of bleeding. This concern is amplified if these supplements are also combined with prescribed blood-thinning medications.
Can Semax be safely combined with Selank?
The combination of Semax and Selank is the most studied combination in the Semax literature – though this should be understood in context: it means that both peptides were studied in overlapping populations and analysed alongside each other in specific studies, rather than in dedicated pharmacokinetic interaction studies specifically designed to assess safety when combined.
A brain imaging study of functional connectivity analysed both peptides in the same group of 52 healthy participants [18], and an enkephalinase inhibition study—analysing how well each peptide inhibits the enzymes that break down the brain's natural calming peptides—tested both peptides simultaneously in the same human serum samples [5]. This provides the closest available data on their combined pharmacological effects.
Both peptides inhibit the enzymes that break down enkephalins in human serum. Semax does so with an IC50 of 10 micromoles, whilst Selank has an IC50 of 20 micromoles [5]. IC50 is a standard measure representing the concentration required to achieve 50% inhibition. Their combination would be expected to result in greater combined inhibition of these enzymes — meaning that the brain’s natural enkephalins would remain active for longer — than either compound alone. This additive effect on the enkephalin system is worth noting, although it has not been associated with any adverse outcomes in the published literature.
The general pharmacological compatibility of Semax and Selank appears reasonable based on their complementary profiles—Semax being more activating and nootropic, Selank more sedating and anxiolytic—and the lack of reported adverse interactions in Russian clinical literature where both are used. However, formal pharmacokinetic and pharmacodynamic interaction studies—studies specifically designed to measure how two compounds affect each other’s behaviour in the body—have not been published for this combination. Characterising their combination as compatible is based on a lack of reported issues, rather than proven safety through a controlled study.
What is the general risk profile of Semax drug interactions?
The overall risk profile of drug interactions Semax can be summarised in three levels based on the strength of pharmacological concern.
The interactions causing the most concern – where specific documented evidence provides a mechanistic basis for genuine caution – concern amphetamine-based stimulants due to their demonstrated dopaminergic-enhancing effect in animal studies [9], and anticoagulants due to Semax's own fibrinolytic and antiplatelet activity [12].
Interactions of moderate concern - where pharmacological overlap creates a plausible but unproven risk of interaction - include SSRIs and other serotonergic agents, other dopaminergic stimulants and supplements, blood pressure medications, anti-epileptic drugs used in seizure disorders, and thyroid medications.
The category of lower concern, where significant pharmacological overlap is absent and the risk of interactions appears theoretically limited, covers most standard vitamins, minerals, and non-psychoactive supplements, as well as the Semax-Selank combination based on its relatively complementary pharmacological profiles.
This risk stratification is based solely on pharmacological reasoning from individual compound studies, not from formal drug interaction studies. The correct response to this evidence gap is not to continue combining them under the assumption of safety. Instead, consulting with a healthcare professional who can assess the individual medical context — including existing conditions, concomitant medications, and personal risk factors — before combining Semax with any prescription medication or high-dose supplement, is the most medically sound approach.
Disclaimer
This article is for educational, informational, and scientific purposes only and should not be interpreted as medical advice, diagnosis, therapeutic recommendation, or a claim regarding the safety or efficacy of Semax for any condition. Semax remains an investigational compound in most countries, including the United States and most European nations, and is not approved by the US Food and Drug Administration (FDA) or the European Medicines Agency (EMA) for the treatment of any medical condition. It is approved and clinically used in Russia and some Eastern European countries. Most of the evidence presented in this paper comes from preclinical animal studies and a limited number of human clinical trials. Additional, well-designed clinical research is needed to more accurately determine the safety, efficacy, mechanisms of action, and long-term effects of Semax in humans.
References
[1] Shypshyna, M. S., Veselovsky, N. S., Myasoedov, N. F., Shram, S. I., & Fedulova, S. A. (2015). Effect of peptide Semax on synaptic activity and short-term plasticity of glutamatergic synapses of co-cultured dorsal root ganglion and dorsal horn neurons. Physiological Journal, 61(4), 48–55. https://doi.org/10.15407/fz61.04.048
[2] Eremin, K. O., Kudrin, V. S., Saransaari, P., Oja, S. S., Grivennikov, I. A., Myasoedov, N. F., & Rayevsky, K. S. (2005). Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents. Neurochemical Research, 30(12), 1493–1500. https://doi.org/10.1007/s11064-005-8826-8
[3] Dolotov, O. V., Karpenko, E. A., Inozemtseva, L. S., Seredenina, T. S., Levitskaya, N. G., Rozyczka, J., Dubynina, E. V., Novosadova, E. V., Andreeva, L. A., Alfeeva, L. Yu., Kamensky, A. A., Grivennikov, I. A., Myasoedov, N. F., & Engele, J. (2006). Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Research, 1117(1), 54–60. https://doi.org/10.1016/j.brainres.2006.07.108
[4] Lebedeva, I. S., Panikratova, Ya. R., Sokolov, O. Yu., Kupriyanov, D. A., Rumshiskaya, A. D., Kost, N. V., & Myasoedov, N. F. (2018). Effects of Semax on the default mode network of the brain. Bulletin of Experimental Biology and Medicine, 165(5), 653–656. https://doi.org/10.1007/s10517-018-4234-3
[5] Kost, N. V., Sokolov, O. Yu., Gabaeva, M. V., Grivennikov, I. A., Andreeva, L. A., Miasoedov, N. F., & Zozulia, A. A. (2001). Semax and selank inhibit the enkephalin-degrading enzymes from human serum. Organic Chemistry, 27(3), 180–183. https://doi.org/10.1023/a:1011373002885
[6] Shadrina, M. I., Dolotov, O. V., Grivennikov, I. A., Slominsky, P. A., Andreeva, L. A., Inozemtseva, L. S., Limborska, S. A., & Myasoedov, N. F. (2001). Rapid induction of neurotrophin mRNAs in rat glial cell cultures by Semax, an adrenocorticotropic hormone analog. Neuroscience Letters, 308(2), 115–118. https://doi.org/10.1016/s0304-3940(01)01994-2
[7] Vilenskiĭ, D. A., Levitskaia, N. G., Andreeva, L. A., Alfeeva, L. Yu., Kamenskiĭ, A. A., & Miasoedov, N. F. (2007). Effects of chronic Semax administration on exploratory activity and emotional reaction in white rats. Rossiyskiy Fiziologicheskiy Zhurnal imeni I.M. Sechenova, 93(6), 661–669. PMID: 17850024
[8] Glazova, N. Yu., Manchenko, D. M., Volodina, M. A., Merchieva, S. A., Andreeva, L. A., Kudrin, V. S., Myasoedov, N. F., & Levitskaya, N. G. (2021). Semax, synthetic ACTH(4-10) analogue, attenuates behavioural and neurochemical alterations following early-life fluvoxamine exposure in white rats. Neuropeptides, 86, 102114. https://doi.org/10.1016/j.npep.2020.102114
[9] Eremin, K. O., Saransaari, P., Oja, S., & Raevskiĭ, K. S. (2004). Semax potentiates effects of D-amphetamine on the level of extracellular dopamine in the Sprague-Dawley rat striatum and on the locomotor activity of C57BL/6 mice. Experimental and Clinical Pharmacology, 67(2), 8–11. PMID: 15188751
Arushanian, E. B., & Popov, A. V. (2009). Effect of semax on heart rate variability in various daytime periods. Experimental and Clinical Pharmacology, 72(2), 32–34. PMID: 19441725
[11] Gorbacheva, A. M., Berdalin, A. B., Stulova, A. N., Nikogosova, A. D., Lin, M. D., Buravkov, S. V., Gavrilova, S. A., & Koshelev, V. B. (2016). Changes in sympathetic innervation of the rat caudal artery in experimental myocardial infarction: Effect of Semax peptide. Bulletin of Experimental Biology and Medicine, 161(4), 476–480. https://doi.org/10.1007/s10517-016-3442-y
[12] Grigorjeva, M. E., & Lyapina, L. A. (2010). Anticoagulant and antiplatelet effects of semax under conditions of acute and chronic immobilisation stress. Bulletin of Experimental Biology and Medicine, 149(1), 44–46. https://doi.org/10.1007/s10517-010-0871-x
[13] Alekseeva, G. V., Bottaev, N. A., & Goroshkova, V. V. (1999). Use of Semax in the follow-up of patients with posthypoxic encephalopathy. Anaesthesiology and Resuscitation, 40–43. PMID: 10199046
Firstova, Yu. Yu., Vasil’eva, E. V., & Kovalev, G. I. (2011). Studying specific effects of nootropic drugs on glutamate receptors in the rat brain. Experimental and Clinical Pharmacology, 74(1), 6–10. PMID: 21476267
[15] Vyunova, T. V., Andreeva, L. A., Shevchenko, K. V., & Myasoedov, N. F. (2019). An integrated approach to study the molecular aspects of regulatory peptides' biological mechanism. Journal of Labelled Compounds and Radiopharmaceuticals, 62(12), 812–822. https://doi.org/10.1002/jlcr.3785
[16] Iasnetsov, V. V., & Voronina, T. A. (2009). Effect of semax and mexidol on brain ischaemia models in rats. Experimental and Clinical Pharmacology, 72(1), 68–70. PMID: 19334516
[17] Storozhevykh, T. P., Tukhbatova, G. R., Senilova, Ya. E., Pinelis, V. G., Andreeva, L. A., & Myasoyedov, N. F. (2007). Effects of semax and its Pro-Gly-Pro fragment on calcium homeostasis of neurons and their survival under conditions of glutamate toxicity. Bulletin of Experimental Biology and Medicine, 143(5), 601–604. https://doi.org/10.1007/s10517-007-0192-x
[18] Panikratova, Ya. R., Lebedeva, I. S., Sokolov, O. Yu., Rumshiskaya, A. D., Kupriyanov, D. A., Kost, N. V., & Myasoedov, N. F. (2020). Functional connectomic approach to studying Selank and Semax effects. Doklady Biological Sciences, 490(1), 9–11. https://doi.org/10.1134/S001249662001007X